 Annabelle Volgman
Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 24 | 2023 | 234 | 7.990 |
Why?
| | Cardiovascular Diseases | 20 | 2023 | 446 | 5.440 |
Why?
| | Stroke | 21 | 2023 | 405 | 4.480 |
Why?
| | Female | 77 | 2023 | 18423 | 2.080 |
Why?
| | Anticoagulants | 7 | 2022 | 153 | 2.050 |
Why?
| | Heart Failure | 7 | 2022 | 241 | 1.920 |
Why?
| | Humans | 99 | 2023 | 32988 | 1.910 |
Why?
| | Healthcare Disparities | 6 | 2020 | 91 | 1.860 |
Why?
| | Coronary Artery Disease | 8 | 2022 | 173 | 1.830 |
Why?
| | Myocardial Infarction | 10 | 2022 | 194 | 1.750 |
Why?
| | Sex Factors | 18 | 2022 | 548 | 1.750 |
Why?
| | Pregnancy Complications, Cardiovascular | 6 | 2023 | 17 | 1.740 |
Why?
| | Risk Factors | 30 | 2023 | 2762 | 1.630 |
Why?
| | Exercise | 7 | 2022 | 494 | 1.510 |
Why?
| | Cardiology | 5 | 2022 | 115 | 1.460 |
Why?
| | Risk Assessment | 14 | 2022 | 814 | 1.420 |
Why?
| | Hospital Mortality | 7 | 2022 | 197 | 1.410 |
Why?
| | Sex Characteristics | 7 | 2023 | 139 | 1.410 |
Why?
| | Hospitalization | 8 | 2021 | 367 | 1.350 |
Why?
| | Myocardial Ischemia | 4 | 2022 | 64 | 1.350 |
Why?
| | Life Style | 8 | 2020 | 226 | 1.340 |
Why?
| | Women's Health | 4 | 2020 | 247 | 1.310 |
Why?
| | Aortic Valve Stenosis | 3 | 2023 | 33 | 1.300 |
Why?
| | Transcatheter Aortic Valve Replacement | 3 | 2023 | 33 | 1.300 |
Why?
| | Cardiovascular System | 3 | 2022 | 15 | 1.280 |
Why?
| | Primary Prevention | 4 | 2022 | 53 | 1.270 |
Why?
| | Physicians, Women | 3 | 2022 | 19 | 1.200 |
Why?
| | Aged | 40 | 2022 | 10542 | 1.200 |
Why?
| | Male | 47 | 2023 | 17726 | 1.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 86 | 1.160 |
Why?
| | Catheter Ablation | 3 | 2022 | 88 | 1.120 |
Why?
| | Pacemaker, Artificial | 3 | 2023 | 52 | 1.120 |
Why?
| | United States | 26 | 2023 | 2632 | 1.110 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 32 | 1.070 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2020 | 46 | 1.070 |
Why?
| | Health Status Disparities | 4 | 2019 | 73 | 1.060 |
Why?
| | Arrhythmias, Cardiac | 6 | 2019 | 172 | 1.030 |
Why?
| | Defibrillators, Implantable | 3 | 2021 | 41 | 1.000 |
Why?
| | Anti-Arrhythmia Agents | 7 | 2022 | 109 | 0.980 |
Why?
| | American Heart Association | 4 | 2023 | 39 | 0.970 |
Why?
| | Ischemic Attack, Transient | 2 | 2023 | 28 | 0.960 |
Why?
| | Middle Aged | 32 | 2022 | 11219 | 0.920 |
Why?
| | Echocardiography, Doppler, Color | 2 | 2019 | 15 | 0.900 |
Why?
| | Myocarditis | 1 | 2022 | 8 | 0.890 |
Why?
| | Quality of Life | 6 | 2023 | 747 | 0.890 |
Why?
| | Premature Birth | 1 | 2022 | 7 | 0.890 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 73 | 0.830 |
Why?
| | Coronavirus | 1 | 2021 | 2 | 0.830 |
Why?
| | Pregnancy | 9 | 2023 | 466 | 0.820 |
Why?
| | Electrocardiography | 7 | 2015 | 230 | 0.810 |
Why?
| | Breast Neoplasms | 3 | 2021 | 435 | 0.800 |
Why?
| | Length of Stay | 4 | 2020 | 382 | 0.780 |
Why?
| | Chest Pain | 1 | 2020 | 23 | 0.770 |
Why?
| | Endothelium | 1 | 2020 | 13 | 0.760 |
Why?
| | Social Media | 1 | 2021 | 37 | 0.760 |
Why?
| | Patient Care Management | 2 | 2021 | 18 | 0.740 |
Why?
| | Brain Ischemia | 1 | 2021 | 125 | 0.730 |
Why?
| | Vascular Diseases | 1 | 2020 | 53 | 0.730 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2019 | 20 | 0.720 |
Why?
| | Myxoma | 1 | 2019 | 7 | 0.720 |
Why?
| | Ambulatory Care Facilities | 2 | 2022 | 45 | 0.720 |
Why?
| | Cardiomyopathies | 1 | 2019 | 38 | 0.710 |
Why?
| | Heart Neoplasms | 1 | 2019 | 21 | 0.700 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 2 | 0.700 |
Why?
| | Comorbidity | 5 | 2021 | 563 | 0.690 |
Why?
| | Women's Health Services | 1 | 2018 | 12 | 0.690 |
Why?
| | Treatment Outcome | 14 | 2023 | 4036 | 0.690 |
Why?
| | Age Factors | 8 | 2021 | 932 | 0.680 |
Why?
| | Heart Diseases | 1 | 2020 | 104 | 0.670 |
Why?
| | Culturally Competent Care | 1 | 2018 | 12 | 0.670 |
Why?
| | Hypertension | 7 | 2023 | 293 | 0.670 |
Why?
| | Prevalence | 6 | 2020 | 554 | 0.670 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 31 | 0.670 |
Why?
| | Emigrants and Immigrants | 1 | 2018 | 25 | 0.660 |
Why?
| | Coronavirus Infections | 1 | 2020 | 96 | 0.650 |
Why?
| | Warfarin | 3 | 2016 | 61 | 0.650 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 101 | 0.650 |
Why?
| | Heart Ventricles | 1 | 2019 | 225 | 0.650 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 244 | 0.630 |
Why?
| | Atherosclerosis | 1 | 2018 | 78 | 0.620 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 10 | 0.580 |
Why?
| | Cognition | 3 | 2020 | 1325 | 0.560 |
Why?
| | Dyslipidemias | 1 | 2016 | 28 | 0.560 |
Why?
| | Prognosis | 7 | 2021 | 1011 | 0.550 |
Why?
| | Electrodes | 1 | 2015 | 17 | 0.540 |
Why?
| | Diabetes Mellitus | 3 | 2022 | 160 | 0.530 |
Why?
| | Secondary Prevention | 3 | 2022 | 69 | 0.530 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2022 | 233 | 0.530 |
Why?
| | Cost of Illness | 1 | 2015 | 66 | 0.520 |
Why?
| | Social Support | 1 | 2016 | 226 | 0.510 |
Why?
| | Electric Countershock | 6 | 2020 | 30 | 0.490 |
Why?
| | Patient Readmission | 3 | 2019 | 134 | 0.480 |
Why?
| | Aspirin | 2 | 2020 | 96 | 0.480 |
Why?
| | Aortic Valve | 3 | 2023 | 44 | 0.470 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 1315 | 0.470 |
Why?
| | Aged, 80 and over | 9 | 2021 | 5249 | 0.460 |
Why?
| | Retrospective Studies | 10 | 2022 | 3835 | 0.430 |
Why?
| | Adult | 14 | 2022 | 9848 | 0.430 |
Why?
| | Atrial Appendage | 2 | 2022 | 53 | 0.420 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 90 | 0.420 |
Why?
| | Coronary Angiography | 3 | 2020 | 115 | 0.410 |
Why?
| | Alzheimer Disease | 1 | 2023 | 1977 | 0.400 |
Why?
| | Acute Kidney Injury | 2 | 2021 | 67 | 0.380 |
Why?
| | Cardiovascular Agents | 2 | 2021 | 33 | 0.370 |
Why?
| | Cardiac Resynchronization Therapy Devices | 2 | 2019 | 10 | 0.370 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 1058 | 0.360 |
Why?
| | Hospital Costs | 2 | 2020 | 74 | 0.360 |
Why?
| | Feasibility Studies | 2 | 2020 | 282 | 0.350 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 388 | 0.320 |
Why?
| | Ventricular Fibrillation | 2 | 2021 | 38 | 0.310 |
Why?
| | Percutaneous Coronary Intervention | 3 | 2022 | 31 | 0.310 |
Why?
| | Heart Atria | 2 | 2019 | 97 | 0.310 |
Why?
| | Administration, Oral | 3 | 2016 | 158 | 0.270 |
Why?
| | Health Status | 2 | 2018 | 247 | 0.270 |
Why?
| | Sex Distribution | 3 | 2019 | 92 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2020 | 377 | 0.270 |
Why?
| | Antihypertensive Agents | 2 | 2020 | 93 | 0.260 |
Why?
| | Hemorrhage | 5 | 2020 | 95 | 0.260 |
Why?
| | Societies, Medical | 3 | 2023 | 214 | 0.260 |
Why?
| | Risk Adjustment | 2 | 2021 | 14 | 0.260 |
Why?
| | Hospital Charges | 2 | 2020 | 20 | 0.250 |
Why?
| | Incidence | 4 | 2020 | 840 | 0.240 |
Why?
| | Logistic Models | 3 | 2021 | 474 | 0.240 |
Why?
| | Obesity | 4 | 2020 | 359 | 0.240 |
Why?
| | Illinois | 2 | 2021 | 267 | 0.240 |
Why?
| | Cardiotoxicity | 2 | 2020 | 5 | 0.240 |
Why?
| | Leadership | 2 | 2022 | 112 | 0.240 |
Why?
| | Cohort Studies | 4 | 2022 | 2077 | 0.240 |
Why?
| | Pulmonary Veins | 1 | 2023 | 25 | 0.240 |
Why?
| | Age Distribution | 2 | 2020 | 109 | 0.230 |
Why?
| | Maternal Mortality | 1 | 2023 | 5 | 0.230 |
Why?
| | Cost-Benefit Analysis | 2 | 2022 | 159 | 0.230 |
Why?
| | Morbidity | 2 | 2019 | 72 | 0.230 |
Why?
| | Young Adult | 3 | 2020 | 2287 | 0.230 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2022 | 5 | 0.230 |
Why?
| | Philippines | 1 | 2022 | 5 | 0.220 |
Why?
| | Health Promotion | 2 | 2016 | 188 | 0.220 |
Why?
| | Pregnancy Outcome | 1 | 2022 | 22 | 0.220 |
Why?
| | Pregnant Women | 1 | 2022 | 17 | 0.220 |
Why?
| | Cesarean Section | 1 | 2022 | 34 | 0.220 |
Why?
| | Polypharmacy | 1 | 2022 | 10 | 0.220 |
Why?
| | Vitamin K | 1 | 2022 | 11 | 0.220 |
Why?
| | Attitude | 1 | 2022 | 38 | 0.220 |
Why?
| | Sotalol | 1 | 2021 | 11 | 0.220 |
Why?
| | Cardiac Electrophysiology | 1 | 2021 | 3 | 0.210 |
Why?
| | Coronary Circulation | 2 | 2020 | 49 | 0.210 |
Why?
| | Pandemics | 2 | 2023 | 253 | 0.210 |
Why?
| | Troponin | 1 | 2021 | 11 | 0.210 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 58 | 0.210 |
Why?
| | Shock, Cardiogenic | 1 | 2021 | 11 | 0.210 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2021 | 4 | 0.210 |
Why?
| | Sexism | 1 | 2021 | 9 | 0.210 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2021 | 3 | 0.210 |
Why?
| | Hormones | 1 | 2021 | 18 | 0.210 |
Why?
| | Prospective Studies | 3 | 2023 | 2002 | 0.210 |
Why?
| | Adolescent | 2 | 2020 | 2687 | 0.210 |
Why?
| | Death, Sudden, Cardiac | 1 | 2021 | 33 | 0.200 |
Why?
| | Women's Rights | 1 | 2021 | 3 | 0.200 |
Why?
| | Overweight | 1 | 2022 | 76 | 0.200 |
Why?
| | Alcohol Drinking | 1 | 2022 | 88 | 0.200 |
Why?
| | Telemedicine | 1 | 2023 | 117 | 0.200 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 35 | 0.200 |
Why?
| | Weight Loss | 1 | 2022 | 116 | 0.200 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 1998 | 43 | 0.200 |
Why?
| | Angioplasty | 1 | 2020 | 17 | 0.200 |
Why?
| | Health Expenditures | 1 | 2020 | 19 | 0.200 |
Why?
| | Physician-Patient Relations | 1 | 2021 | 47 | 0.200 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2022 | 79 | 0.200 |
Why?
| | Hyperlipidemias | 1 | 2020 | 26 | 0.200 |
Why?
| | Career Choice | 1 | 2021 | 34 | 0.200 |
Why?
| | Heart Valve Diseases | 1 | 2020 | 33 | 0.200 |
Why?
| | Disease Outbreaks | 1 | 2021 | 91 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 29 | 0.200 |
Why?
| | Periodicals as Topic | 1 | 2021 | 47 | 0.190 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 24 | 0.190 |
Why?
| | Myocardial Revascularization | 1 | 2020 | 25 | 0.190 |
Why?
| | Postnatal Care | 1 | 2020 | 9 | 0.190 |
Why?
| | Accidental Falls | 1 | 2022 | 118 | 0.190 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 15 | 0.190 |
Why?
| | Radiation-Protective Agents | 1 | 2020 | 4 | 0.190 |
Why?
| | Colchicine | 1 | 2020 | 9 | 0.190 |
Why?
| | Protective Factors | 1 | 2020 | 19 | 0.190 |
Why?
| | Social Class | 1 | 2020 | 77 | 0.190 |
Why?
| | After-Hours Care | 1 | 2019 | 1 | 0.190 |
Why?
| | Income | 1 | 2020 | 81 | 0.190 |
Why?
| | Endovascular Procedures | 1 | 2020 | 84 | 0.180 |
Why?
| | Odds Ratio | 2 | 2020 | 321 | 0.180 |
Why?
| | Prostatic Neoplasms | 1 | 2021 | 125 | 0.180 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 53 | 0.180 |
Why?
| | Infant, Newborn | 1 | 2022 | 761 | 0.180 |
Why?
| | Radiation Injuries | 1 | 2020 | 44 | 0.180 |
Why?
| | Global Health | 1 | 2019 | 61 | 0.180 |
Why?
| | Thrombolytic Therapy | 1 | 2020 | 84 | 0.180 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 368 | 0.180 |
Why?
| | Health Behavior | 1 | 2020 | 181 | 0.180 |
Why?
| | Up-Regulation | 2 | 2021 | 225 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2019 | 24 | 0.180 |
Why?
| | Multimodal Imaging | 1 | 2019 | 30 | 0.180 |
Why?
| | Heart | 1 | 2019 | 119 | 0.170 |
Why?
| | Treatment Refusal | 1 | 2018 | 14 | 0.170 |
Why?
| | Asia, Western | 1 | 2018 | 2 | 0.170 |
Why?
| | Indian Ocean Islands | 1 | 2018 | 2 | 0.170 |
Why?
| | Procainamide | 1 | 1998 | 23 | 0.170 |
Why?
| | Heart Transplantation | 1 | 1998 | 51 | 0.170 |
Why?
| | Atrial Flutter | 1 | 1998 | 24 | 0.170 |
Why?
| | Graft Rejection | 1 | 1998 | 87 | 0.170 |
Why?
| | Tachycardia | 2 | 2021 | 49 | 0.170 |
Why?
| | Intensive Care Units | 1 | 2021 | 339 | 0.160 |
Why?
| | Sulfonamides | 1 | 1998 | 60 | 0.160 |
Why?
| | Walking | 1 | 2020 | 277 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2017 | 893 | 0.160 |
Why?
| | Memory Disorders | 1 | 2019 | 181 | 0.160 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 462 | 0.160 |
Why?
| | Inpatients | 1 | 2019 | 163 | 0.160 |
Why?
| | Coronary Disease | 2 | 2020 | 101 | 0.160 |
Why?
| | Diet Surveys | 1 | 2017 | 27 | 0.150 |
Why?
| | Patient Discharge | 1 | 2018 | 169 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 207 | 0.150 |
Why?
| | Pyridones | 1 | 2016 | 18 | 0.150 |
Why?
| | Nutrition Assessment | 1 | 2017 | 52 | 0.150 |
Why?
| | Thiazoles | 1 | 2016 | 38 | 0.150 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 235 | 0.150 |
Why?
| | Evidence-Based Practice | 1 | 2017 | 86 | 0.150 |
Why?
| | Pyridines | 1 | 2016 | 47 | 0.150 |
Why?
| | Neoplasms | 1 | 2020 | 280 | 0.150 |
Why?
| | Echocardiography | 4 | 2023 | 207 | 0.150 |
Why?
| | Patient Selection | 2 | 2020 | 261 | 0.150 |
Why?
| | Georgia | 1 | 2016 | 16 | 0.140 |
Why?
| | Coronary Vessels | 2 | 2021 | 56 | 0.140 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 592 | 0.140 |
Why?
| | Pyrazoles | 1 | 2016 | 53 | 0.140 |
Why?
| | Cholesterol, LDL | 1 | 2016 | 46 | 0.140 |
Why?
| | Dementia | 1 | 2022 | 568 | 0.140 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 68 | 0.140 |
Why?
| | Diet, Mediterranean | 1 | 2017 | 72 | 0.140 |
Why?
| | Health Surveys | 1 | 2016 | 102 | 0.140 |
Why?
| | Self Efficacy | 1 | 2016 | 66 | 0.140 |
Why?
| | Miniaturization | 1 | 2015 | 2 | 0.140 |
Why?
| | Preventive Health Services | 1 | 2015 | 16 | 0.140 |
Why?
| | Chicago | 2 | 2016 | 957 | 0.140 |
Why?
| | Equipment Design | 2 | 2015 | 207 | 0.130 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 117 | 0.130 |
Why?
| | Heart Rate | 2 | 2009 | 165 | 0.130 |
Why?
| | Smoking | 2 | 2018 | 206 | 0.120 |
Why?
| | Needs Assessment | 1 | 2013 | 50 | 0.120 |
Why?
| | Cardiac Pacing, Artificial | 2 | 1992 | 84 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2012 | 28 | 0.110 |
Why?
| | Heart Conduction System | 1 | 1992 | 38 | 0.110 |
Why?
| | Activities of Daily Living | 1 | 2016 | 515 | 0.110 |
Why?
| | Data Collection | 1 | 2012 | 118 | 0.110 |
Why?
| | Registries | 3 | 2022 | 226 | 0.110 |
Why?
| | Blood Pressure | 2 | 2023 | 270 | 0.100 |
Why?
| | Motor Activity | 1 | 2013 | 391 | 0.090 |
Why?
| | Coronary Artery Bypass | 2 | 2020 | 74 | 0.090 |
Why?
| | Survival Rate | 2 | 2019 | 443 | 0.080 |
Why?
| | Databases, Factual | 2 | 2019 | 393 | 0.080 |
Why?
| | Azetidines | 1 | 2006 | 4 | 0.070 |
Why?
| | Benzylamines | 1 | 2006 | 15 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2021 | 1242 | 0.070 |
Why?
| | Body Mass Index | 2 | 2020 | 478 | 0.070 |
Why?
| | Time Factors | 3 | 2021 | 1873 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2004 | 31 | 0.070 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 7 | 0.060 |
Why?
| | Pharmacists | 1 | 2023 | 19 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2020 | 1117 | 0.060 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2022 | 15 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2019 | 2053 | 0.060 |
Why?
| | Flecainide | 1 | 2021 | 14 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2006 | 546 | 0.050 |
Why?
| | Microcirculation | 1 | 2021 | 40 | 0.050 |
Why?
| | Genetic Testing | 1 | 2022 | 77 | 0.050 |
Why?
| | Ischemia | 1 | 2021 | 35 | 0.050 |
Why?
| | Palliative Care | 1 | 2023 | 158 | 0.050 |
Why?
| | Pregnancy, High-Risk | 1 | 2021 | 2 | 0.050 |
Why?
| | Peripartum Period | 1 | 2021 | 3 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2023 | 166 | 0.050 |
Why?
| | Chlorides | 1 | 2021 | 26 | 0.050 |
Why?
| | Diuretics | 1 | 2021 | 15 | 0.050 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 104 | 0.050 |
Why?
| | Recurrence | 2 | 2006 | 400 | 0.050 |
Why?
| | Health Services Research | 1 | 2021 | 44 | 0.050 |
Why?
| | Sodium | 1 | 2021 | 87 | 0.050 |
Why?
| | Education, Medical | 1 | 2021 | 48 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 71 | 0.050 |
Why?
| | Patient Preference | 1 | 2021 | 38 | 0.050 |
Why?
| | Fetal Growth Retardation | 1 | 2020 | 4 | 0.050 |
Why?
| | Hypercholesterolemia | 1 | 2020 | 39 | 0.050 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2020 | 4 | 0.050 |
Why?
| | Abortion, Spontaneous | 1 | 2020 | 9 | 0.050 |
Why?
| | Menopause, Premature | 1 | 2020 | 7 | 0.050 |
Why?
| | Sleep Apnea, Central | 1 | 2000 | 26 | 0.050 |
Why?
| | Lactation | 1 | 2021 | 79 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2000 | 694 | 0.050 |
Why?
| | Health Care Costs | 1 | 2020 | 83 | 0.050 |
Why?
| | Attitude to Health | 1 | 2020 | 116 | 0.050 |
Why?
| | Radiotherapy | 1 | 2020 | 62 | 0.050 |
Why?
| | Curriculum | 1 | 2021 | 173 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 39 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 67 | 0.040 |
Why?
| | Cause of Death | 1 | 2019 | 83 | 0.040 |
Why?
| | Thrombectomy | 1 | 2019 | 53 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2020 | 386 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 138 | 0.040 |
Why?
| | Psychology | 1 | 2018 | 24 | 0.040 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 70 | 0.040 |
Why?
| | Heredity | 1 | 2018 | 7 | 0.040 |
Why?
| | Diet, Western | 1 | 2017 | 8 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 230 | 0.040 |
Why?
| | Quality Improvement | 1 | 2018 | 173 | 0.040 |
Why?
| | Breast Feeding | 1 | 2018 | 186 | 0.040 |
Why?
| | Waist Circumference | 1 | 2015 | 37 | 0.040 |
Why?
| | Risk | 1 | 2016 | 228 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 261 | 0.030 |
Why?
| | Body Composition | 1 | 2016 | 78 | 0.030 |
Why?
| | Body Weight | 1 | 2016 | 167 | 0.030 |
Why?
| | Decision Making | 1 | 2018 | 239 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 467 | 0.030 |
Why?
| | Patient Compliance | 1 | 2016 | 200 | 0.030 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 1993 | 3 | 0.030 |
Why?
| | Dextroamphetamine | 1 | 1993 | 6 | 0.030 |
Why?
| | Social Networking | 1 | 2013 | 10 | 0.030 |
Why?
| | Hypotension, Orthostatic | 1 | 1993 | 17 | 0.030 |
Why?
| | Efficiency | 1 | 2013 | 21 | 0.030 |
Why?
| | Syncope | 1 | 1993 | 11 | 0.030 |
Why?
| | Albuterol | 1 | 1993 | 20 | 0.030 |
Why?
| | Bradycardia | 1 | 1993 | 32 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2013 | 152 | 0.030 |
Why?
| | Program Evaluation | 1 | 2013 | 150 | 0.030 |
Why?
| | Tachycardia, Ventricular | 1 | 1992 | 44 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 1992 | 116 | 0.030 |
Why?
| | Asthma | 1 | 1993 | 194 | 0.020 |
Why?
| | Animals | 1 | 2020 | 5371 | 0.020 |
Why?
| | Estrogen Replacement Therapy | 1 | 2006 | 22 | 0.020 |
Why?
| | Thromboembolism | 1 | 2006 | 38 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 177 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 387 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2004 | 449 | 0.010 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2000 | 24 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2000 | 38 | 0.010 |
Why?
| | Respiration | 1 | 2000 | 37 | 0.010 |
Why?
| | Tracheostomy | 1 | 2000 | 28 | 0.010 |
Why?
| | Anesthesia | 1 | 2000 | 35 | 0.010 |
Why?
| | Child | 1 | 2000 | 1634 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1993 | 38 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1993 | 42 | 0.010 |
Why?
| | Posture | 1 | 1993 | 90 | 0.010 |
Why?
| | Action Potentials | 1 | 1993 | 151 | 0.010 |
Why?
| | ROC Curve | 1 | 1992 | 155 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1992 | 358 | 0.010 |
Why?
|
|
Volgman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|